CL2012002014A1 - Pharmaceutical formulation of modified release containing 30-70% of the ethyl ester of the n- (2-amino-4- (fluorobenzylamino) -phenyl) carbamic acid (retigabine), 5-30% of a hydroxypropyl methylcellulose (hpmc) matrix and a enteric polymer; method of treatment of a disorder caused by hyperexcitability of the nervous system. - Google Patents

Pharmaceutical formulation of modified release containing 30-70% of the ethyl ester of the n- (2-amino-4- (fluorobenzylamino) -phenyl) carbamic acid (retigabine), 5-30% of a hydroxypropyl methylcellulose (hpmc) matrix and a enteric polymer; method of treatment of a disorder caused by hyperexcitability of the nervous system.

Info

Publication number
CL2012002014A1
CL2012002014A1 CL2012002014A CL2012002014A CL2012002014A1 CL 2012002014 A1 CL2012002014 A1 CL 2012002014A1 CL 2012002014 A CL2012002014 A CL 2012002014A CL 2012002014 A CL2012002014 A CL 2012002014A CL 2012002014 A1 CL2012002014 A1 CL 2012002014A1
Authority
CL
Chile
Prior art keywords
retigabine
fluorobenzylamino
hyperexcitability
hpmc
phenyl
Prior art date
Application number
CL2012002014A
Other languages
Spanish (es)
Inventor
Biljana Nadjsombati
Original Assignee
Valeant Pharmaceuticals Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47042234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012002014(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US12/690,889 external-priority patent/US20100323015A1/en
Priority claimed from US12/691,680 external-priority patent/US20100323016A1/en
Application filed by Valeant Pharmaceuticals Int filed Critical Valeant Pharmaceuticals Int
Publication of CL2012002014A1 publication Critical patent/CL2012002014A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Formulación farmacéutica de liberación modificada que contiene 30-70 % del éster etílico del ácido n-(2-amino-4-(fluorobencilamino)-fenil)carbámico (retigabina), 5-30 % de una matriz de hidroxipropilmetilcelulosa (HPMC) y un polímero entérico; método de tratamiento de un trastorno provocado por hiperexcitabilidad del sistema nervioso.Modified-release pharmaceutical formulation containing 30-70% of the n- (2-amino-4- (fluorobenzylamino) -phenyl) carbamic acid (retigabine) ethyl ester, 5-30% of a hydroxypropylmethylcellulose (HPMC) matrix and a enteric polymer; method of treatment of a disorder caused by hyperexcitability of the nervous system.

CL2012002014A 2010-01-20 2012-07-20 Pharmaceutical formulation of modified release containing 30-70% of the ethyl ester of the n- (2-amino-4- (fluorobenzylamino) -phenyl) carbamic acid (retigabine), 5-30% of a hydroxypropyl methylcellulose (hpmc) matrix and a enteric polymer; method of treatment of a disorder caused by hyperexcitability of the nervous system. CL2012002014A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/690,889 US20100323015A1 (en) 2008-07-18 2010-01-20 Modified release formulation and methods of use
US12/691,680 US20100323016A1 (en) 2008-07-18 2010-01-21 Modified release formulation and methods of use

Publications (1)

Publication Number Publication Date
CL2012002014A1 true CL2012002014A1 (en) 2013-04-05

Family

ID=47042234

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012002014A CL2012002014A1 (en) 2010-01-20 2012-07-20 Pharmaceutical formulation of modified release containing 30-70% of the ethyl ester of the n- (2-amino-4- (fluorobenzylamino) -phenyl) carbamic acid (retigabine), 5-30% of a hydroxypropyl methylcellulose (hpmc) matrix and a enteric polymer; method of treatment of a disorder caused by hyperexcitability of the nervous system.

Country Status (6)

Country Link
EP (1) EP2525660A4 (en)
BR (1) BR112012018173A2 (en)
CL (1) CL2012002014A1 (en)
CO (1) CO6592107A2 (en)
EA (1) EA201290663A1 (en)
MX (1) MX2012008475A (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200200504A (en) * 2000-03-08 2004-02-16 Awd.Pharma Gmbh & Co. Kg Pharmaceutical preparations
JP5563731B2 (en) * 2003-09-26 2014-07-30 アルザ・コーポレーシヨン Controlled release formulation of opioid and non-opioid analgesics
ATE538084T1 (en) * 2006-11-28 2012-01-15 Valeant Pharmaceuticals Int BICYCLIC 1,4-RETIGABINE ANALOGAS AS POTASSIUM CHANNEL INHIBITORS
MX2011000636A (en) * 2008-07-18 2011-08-03 Valeant Pharmaceuticals Int Modified release formulation and methods of use.

Also Published As

Publication number Publication date
EP2525660A1 (en) 2012-11-28
BR112012018173A2 (en) 2017-08-29
CO6592107A2 (en) 2013-01-02
MX2012008475A (en) 2013-11-01
EA201290663A1 (en) 2013-03-29
EP2525660A4 (en) 2013-08-07

Similar Documents

Publication Publication Date Title
CL2011000109A1 (en) Pharmaceutical formulation comprising 30-70% ethyl n- (2-amino-4- (fluorobenzylamino) -phenyl) carbamic acid (retigabine), 5-30% of a matrix comprising hydroxypropyl methylcellulose, 1.0-10% an anionic surfactant and an enteric polymer; and its use to treat a disorder of hyperexitability of the nervous system.
CL2014000630A1 (en) A composition comprising 1) a nucleoside-derived compound called as compound 10 and 2) a compound derived from 5-thiophene-2-carboxylic acid called as compound 5 or a compound derived from the carbamic acid methyl ester called as compound 6; and its use for the prophylactic or therapeutic treatment of a vhc infection.
CL2012001215A1 (en) Vector expression system comprising a first and a second expression cassette where the first cassette encodes a gtp-cyclohydrolase (gch1) and the second encodes a tyrosine hydrolase; vector; host cell; use of the vector to prepare medicament for treating catecholamine associated disease.
BR112014010900A2 (en) methods of preparing catalyst system
BR112013020743A2 (en) compositions and methods for influenza therapy and diagnosis
MX2011013982A (en) Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-e thyl ester.
EA201200728A1 (en) NEW SOKRYSTALY AGOMELATIN, METHOD OF THEIR RECEIVING AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
BR112012014423A2 (en) "system for generating an object construction, medical workstation, medical imaging equipment, method of generating an object construction and computer program product
PH12018501072A1 (en) Modified release orally administered amino acid formulations
CR20150266A (en) MODIFIED RELEASE FORMULATIONS FOR OPROZOMIB
CL2011001405A1 (en) Procedure for the preparation of n- [2- (7-methoxy-1-naphthyl) ethyl] acetamide, agomethalin.
WO2011101863A3 (en) Extended release pharmaceutical compositions of lacosamide
EA201290552A1 (en) METHOD OF MANUFACTURE OF PHARMACEUTICAL ACTIVE SUBSTANCE
CR20150297A (en) COMICRONIZATION PRODUCT THAT INCLUDES ULIPRISTAL ACETATE
BRPI0913391A2 (en) process and system that enables protection of a compressed video stream against errors that occur during a broadcast
MX2012008413A (en) Novel retigabine composition.
CR20130219A (en) PHARMACEUTICAL COMPOSITION OF ORAL ADMINISTRATION FOR THE TREATMENT OF IRRITABLE INTESTINE SYNDROME, BASED ON AN INTESTINAL MOTILITY MODIFIER, AN AGENT THAT PREVENTS THE RETENTION OF DIGESTIVE GASES AND ENZYMES AND PROCESS FOR S
BR112017028224A2 (en) composition, and method for protecting a piglet against a pestivirus-associated disease.
IN2014DN06965A (en)
CL2012002014A1 (en) Pharmaceutical formulation of modified release containing 30-70% of the ethyl ester of the n- (2-amino-4- (fluorobenzylamino) -phenyl) carbamic acid (retigabine), 5-30% of a hydroxypropyl methylcellulose (hpmc) matrix and a enteric polymer; method of treatment of a disorder caused by hyperexcitability of the nervous system.
MX349563B (en) Pharmaceutical formulation of nanonised fenofibrate.
AR091239A1 (en) INFECTIOUS VIRUS OF SCHMALLENBERG OF cDNA CLONATES AND ITS USES
PH12014502325B1 (en) Sustained release tablet containing levodropropizine and method for preparing same
AR093252A1 (en) ORAL PHARMACEUTICAL COMPOSITION USED AS ANTIPARASITARY AND ANTIDIARRICS AND PROCESSES TO PREPARE IT
BR112012020223A2 (en) "orally administrable epidermal growth factor pharmaceutical pellet"